Last reviewed · How we verify
Lactulose Oral Product
At a glance
| Generic name | Lactulose Oral Product |
|---|---|
| Sponsor | Children's Memorial Health Institute, Poland |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Outcome of Fecal Microbiota Transplantation (PHASE1, PHASE2)
- New Mechanisms of Obesity (NA)
- Effect of Probiotic on Gut Microbiota in Young Children With Functional Constipation (PHASE2)
- A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. (PHASE4)
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (PHASE2)
- BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE (PHASE4)
- Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF) (PHASE1)
- Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: PEGASIS Trial (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactulose Oral Product CI brief — competitive landscape report
- Lactulose Oral Product updates RSS · CI watch RSS
- Children's Memorial Health Institute, Poland portfolio CI